Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 5/20 | 1.00 |
| ▸ | LDHA | P00338 | 14/20 | 0.84 |
| ▸ | LDHB | P07195 | 13/20 | 0.84 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.45 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622271 | 1.00 | ALB (1.00) | ALBLDHALDHBMCL1BCL2 | |
| SCHEMBL7173943 | 0.92 | LDHA (1.00) | ALBLDHALDHBMCL1BCL2 | |
| SCHEMBL2622272 | 0.79 | ALB (0.65) | ALBLDHALDHBMCL1KDM4E | |
| SCHEMBL7183463 | 0.78 | LDHA (1.00) | ALBLDHALDHB | |
| SCHEMBL29750641 | 0.77 | LDHA (1.00) | ALBLDHALDHB | |
| SCHEMBL426471 | 0.77 | LDHA (1.00) | ALBLDHALDHB | |
| SCHEMBL10820453 | 0.76 | ALB (1.00) | ALBLDHALDHBMCL1BCL2 | |
| SCHEMBL2622270 | 0.76 | ALB (1.00) | ALBLDHALDHBMCL1BCL2 | |
| SCHEMBL7180825 | 0.76 | LDHA (0.86) | ALBLDHALDHB | |
| SCHEMBL7179527 | 0.76 | LDHA (0.86) | ALBLDHALDHBBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12389702-B2 | Solid-state imaging element | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2025-08-12 | — | — | US | disclosed |
| CN-119766558-A | Method, computer device, program product and medium for detecting malicious domain name | 北京天融信网络安全技术有限公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025071713-A1 | DETECTING ALGORITHMICALLY GENERATED DOMAINS IN REGISTERED DOMAIN DATA | INFOBLOX INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250106226-A1 | DETECTING ALGORITHMICALLY GENERATED DOMAINS IN REGISTERED DOMAIN DATA | INFOBLOX INC. | 2025-03-27 | — | — | US | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-118295054-A | Reflective medium doped supergrating and supergrating array | 安徽大学 | 2024-07-05 | — | — | CN | disclosed |
| US-11834690-B2 | Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid | GENOMATICA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4273255-A2 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | Genomatica, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3611254-B1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF HEXAMETHYLENEDIAMINE | GENOMATICA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-112675314-B | Bone-targeting nano micelle delivery system and preparation method thereof | 中国药科大学 | 2023-02-24 | — | — | CN | disclosed |
| US-20230022727-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220149102-A1 | SOLID-STATE IMAGING ELEMENT | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220098329-A1 | HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ALB 852/4885LDHA 2903/4885LDHB 2469/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | ALB 852/4885LDHA 2903/4885LDHB 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.